Skip to main content
OpenTrials
Completed

NCT Number: NCT03046849

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria

The purpose of this study is to find out the proportion of patients diagnosed with Lynch syndrome in colorectal cacner patients meeting Chinese Lynch syndrome criteria. Besides, this study is aimed to analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.

Completed

Looking for future studies?

Notify Me

Key information

About this study

  • Detect germline mutation (by next-generation squencing) in probands.
  • Verify the germline mutation in blood relatives whose proband has known germline mutation(s).
  • Analyze the test data with clinical and family information. Diagnose Lynch syndrome in the included population.
  • Analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For probands, the inclusion criteria: all of the following three points should be satisfied:

  • One of the colorectal cancer patients from families meeting Chinese Lynch syndrome criteria.

Chinese Lynch syndrome criteria:

In a pedigree, there were at least 2 patients with histological-proven colorectal cancer, and among these, at least two patients are first-degree relatives of each other. Besides, any one of the following three points should be satisfied in the pedigree:

A. at least one patients with multiple primary colorectal carcinoma/adenoma, either synchronously or metachronously.

B. at least one colorectal cancer diagnosed before 50 years old. C. in the pedigree, at least one patient diagnosed with other Lynch syndrome associated cancer (ie, gastric, endometrial, small bowel, ureter, or renal-pelvic, ovarian and hepatobiliary cancers).

  • With sufficient blood to test;
  • Agree to provide basic information, clinical information and family history of cancer information.

For probands, the exclusion criteria:

With at least one blood relative with known pathogenic germline mutation(s).

For blood relatives verifying germline mutation, the inclusion criteria: all of the following three points should be satisfied:

  • First- to second-degree blood relatives of probands with germline mutation(s).
  • With sufficient blood to test.
  • Agree to provide basic information, clinical information and family history of cancer information.

For blood relatives verifying germline mutation, the exclusion criteria:

Blood relatives who refuse to test.

Treatment and study plan

next-generation sequencing

Other

Use next-generation sequencing to test germline mutation.

Primary outcomes

  1. Pathogenic germline mutation

    Time frame: Upon completion of study, on average 2 years.

    Pathogenic germline mutation using next-generation sequencing with a targeted panel.

Secondary outcomes

  1. Variant of uncertain significance of germline mutation

    Time frame: Upon completion of study, on average 2 years.

    Variant of uncertain significance using next-generation sequencing with a targeted panel.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Patients Meeting Chinese Lynch Syndrome Criteria: An Open-label and Multi-center Study.

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Feb 8, 2017
Registry last updated
Aug 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.